The Tisch Cancer Institute | Strategic Alliance Partners

Latest from The Tisch Cancer Institute

Imetelstat Has Disease-Modifying Activity in Relapsed/Refractory Myelofibrosis, as Shown by Effect on Telomerase Activity

January 19, 2021

Article

January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.

Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies

December 28, 2020

Article

Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.

Dr. Brody on the Expanding Role of Venetoclax in MCL

December 03, 2020

Video

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

Dr. Mascarenhas on the Role of Genetic Testing in MPNs

December 02, 2020

Video

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.

Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL

November 25, 2020

Video

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

CAR T-Cell Combinations May Offer a Way to Overcome Antigen Escape in MCL

November 19, 2020

Article

Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.